IRIS
PEA, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.751
AS - Asia 6.477
EU - Europa 4.567
SA - Sud America 956
Continente sconosciuto - Info sul continente non disponibili 715
AF - Africa 122
OC - Oceania 5
Totale 31.593
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.520
SG - Singapore 3.108
CN - Cina 1.257
UA - Ucraina 1.140
BR - Brasile 747
IT - Italia 723
HK - Hong Kong 679
DE - Germania 654
SE - Svezia 493
VN - Vietnam 489
RU - Federazione Russa 354
TR - Turchia 302
FR - Francia 284
FI - Finlandia 237
IE - Irlanda 220
GB - Regno Unito 180
IN - India 145
CA - Canada 109
BD - Bangladesh 77
AR - Argentina 60
IQ - Iraq 52
KR - Corea 52
MX - Messico 49
ID - Indonesia 46
EC - Ecuador 44
JP - Giappone 44
NL - Olanda 44
BE - Belgio 40
CO - Colombia 35
ES - Italia 35
SA - Arabia Saudita 34
CZ - Repubblica Ceca 31
ZA - Sudafrica 30
VE - Venezuela 23
EU - Europa 21
PH - Filippine 20
PL - Polonia 20
PK - Pakistan 18
EG - Egitto 17
IR - Iran 15
LT - Lituania 14
MA - Marocco 14
UZ - Uzbekistan 14
CL - Cile 13
JM - Giamaica 13
KE - Kenya 13
MY - Malesia 13
CH - Svizzera 12
CR - Costa Rica 12
IL - Israele 12
UY - Uruguay 12
JO - Giordania 11
AZ - Azerbaigian 10
HN - Honduras 10
RO - Romania 10
TH - Thailandia 10
BO - Bolivia 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
AL - Albania 8
AT - Austria 8
KZ - Kazakistan 8
PE - Perù 8
PT - Portogallo 8
RS - Serbia 8
BG - Bulgaria 7
DO - Repubblica Dominicana 6
NP - Nepal 6
ET - Etiopia 5
OM - Oman 5
SV - El Salvador 5
TG - Togo 5
TW - Taiwan 5
AU - Australia 4
BB - Barbados 4
GT - Guatemala 4
HU - Ungheria 4
KH - Cambogia 4
KW - Kuwait 4
LB - Libano 4
LV - Lettonia 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
CY - Cipro 3
EE - Estonia 3
GA - Gabon 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
MD - Moldavia 3
PA - Panama 3
PS - Palestinian Territory 3
PY - Paraguay 3
SD - Sudan 3
SY - Repubblica araba siriana 3
BF - Burkina Faso 2
BH - Bahrain 2
BS - Bahamas 2
BY - Bielorussia 2
Totale 30.847
Salva come PNG Salva come JPEG
Città #
Fairfield 2.205
Woodbridge 1.562
Ashburn 1.492
Singapore 1.428
Chandler 1.139
Houston 1.097
Ann Arbor 963
Wilmington 840
Seattle 835
Cambridge 716
Hong Kong 667
Jacksonville 640
Dallas 623
Beijing 590
San Jose 564
Dearborn 427
Council Bluffs 413
Boardman 362
Izmir 271
Princeton 238
Dublin 219
Lauterbourg 217
Udine 194
Des Moines 174
Los Angeles 169
Ho Chi Minh City 135
San Diego 125
Santa Clara 108
Redondo Beach 105
Hanoi 100
New York 98
Buffalo 91
Dong Ket 71
Munich 70
The Dalles 67
Orem 66
Helsinki 59
São Paulo 59
Falls Church 58
Redmond 57
Hefei 51
Norwalk 43
Frankfurt am Main 42
Ogden 41
Milan 40
Phoenix 40
Tokyo 40
Brussels 39
Seoul 38
Chicago 37
Brooklyn 36
Nanjing 36
Grafing 33
Ottawa 30
Montreal 29
Denver 28
Shanghai 27
Amsterdam 26
Moscow 25
Rio de Janeiro 24
Atlanta 23
Brasília 23
London 23
Grugliasco 22
Guangzhou 22
Nuremberg 22
Rome 21
San Francisco 21
Kunming 20
Mumbai 20
Chennai 19
Johannesburg 19
Quito 18
Warsaw 18
Baghdad 17
Jinan 17
Toronto 17
Trieste 17
Belo Horizonte 16
Brno 16
Bologna 15
Curitiba 15
Da Nang 15
Manchester 15
San Mateo 15
Dhaka 14
Riyadh 14
Biên Hòa 13
Boston 13
Düsseldorf 13
Haiphong 13
Jeddah 13
Naples 13
Wuhan 13
Mexico City 12
Paris 12
Philadelphia 12
Piemonte 12
West Jordan 12
Augusta 11
Totale 20.675
Salva come PNG Salva come JPEG
Nome #
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? 773
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? 700
A regional approach to Antimicrobial Stewardship: the Friuli Venezia Giulia program 283
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? 229
Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia 221
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant 215
LONG-TERM OUTCOMES OF ORTHOTOPIC LIVER TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS AND COMPARISON WITH HUMAN IMMUNODEFICIENCY VIRUS-NEGATIVE CASES 210
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 209
Polypharmacy in an Italian Regional Health system: a survey on drugs use in different healthcare settings 207
Pharmacokinetic drug interaction between everolimus and antifungal triazoles in a liver transplant patient 200
Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients 198
Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. 197
Educational and Organizational Interventions to Improve the Usefulness of Clinical Pharmacological Advice for Personalized Drug Dosing Based on Therapeutic Drug Monitoring. 197
Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients 191
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 190
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 189
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: A report of three cases 186
Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy 184
Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function 182
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 181
Ceftolozane/tazobactam: place in therapy 181
- FLUCONAZOLE MONITORING IN LIVER TRANSPLANT RECIPIENTS 180
Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: A case report 180
Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections 176
Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients 171
Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? 171
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use 170
Hyperlactacidemia Potentially Due to Linezolid Overexposure in a Liver Transplant Recipient 170
Monitoring polypharmacy in healthcare systems through a multi-setting survey: Should we put more attention on long term care facilities? 170
Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis 169
Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens 169
Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. 169
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 168
Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): Comparative pharmacokinetics and the role of therapeutic drug monitoring 168
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? 168
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy 168
Linezolid underexposure in a patient co-treated with venlafaxine 167
Antibiotic therapy in hematological neutropenic patients: what is the news? 166
Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus. 166
The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin 165
Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. 165
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions 165
Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: Should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles? 165
Antimicrobial treatment of bacterial infections in frail elderly patients: The difficult balance between efficacy, safety and tolerability 163
Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients 162
Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring 162
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice? 161
Treatment of Candida Infections with Fluconazole in Adult Liver Transplant Recipients: Is TDM-guided Dosing Adaptation Helpful? 160
Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis 159
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis 159
Is MIC increase of meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae correlated with the increase of resistance rates against some other antibiotics with Gram-negative activity? 158
Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience 157
Plasma pharmacokinetics of antimicrobial agents in critically Ill patients 157
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations 157
High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures 156
Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients 156
Biliary pharmacodynamic exposure to linezolid in two liver transplant patients. 155
Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery 154
TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients 154
Effect of fluctuations of blood cyclosporine concentrations on renal function. 153
Blood concentrations and clinical effect of cyclosporin in psoriasis 153
Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp 153
Multidrug resistance modulation in vivo. The effect of cyclosporin alone or with dextro-verapamil on idarubicin pharmacokinetics in acute leukemia 153
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? 152
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections 152
Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective 150
Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: Proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site 150
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia 149
Antimicrobial agents in elective surgery: Prophylaxis or "early therapy"? 149
Pharmacokinetics and drug metabolism of antibiotics in the elderly 149
Pharmacokinetic-pharmacodynamic aspecte of antimicrobial prophylaxis with teisoplanin in patients undergoing major vascular surgery 148
Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis 147
Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia 147
Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy 147
Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin 147
Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis 147
HIV-INFECTED PATIENTS AND LIVER TRANSPLANTATION: WHO, WHEN AND WHY 146
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy 146
Urinary Pharmacokinetics and Theoretical Pharmacodynamics of Intravenous Levofloxacin in Intensive Care Unit Patients Treated with 500 mg b.i.d. for Ventilator-Associated Pneumonia 146
A Comparative Analysis of the Urinary Excretion Profiles of Mesna and Argimesna Following Oral Administration to Healthy Volunteers 143
A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care 143
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients 141
Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient 141
Teicoplanin therapeutic drug monitoring in critically ill patients: A retrospective study emphasizing the importance of a loading dose 140
The role of Clinical Pharmacology advices based on therapeutic drug monitoring in tailoring antimicrobial therapy in critical ill children . 138
Liposome-encapsulated daunorubicin for PGP-related multidrug resistance 138
Reappraisal of Linezolid Dosing in Renal Impairment to Improve Safety 138
Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderly at higher risk of PIPs? 138
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 137
Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: A pharmacokinetics/pharmacodynamics-based approach 137
Gentamicin once-daily in enterococcal endocarditis 137
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure 136
Daptomycin in solid organ transplantation: Consideration of dosage adjustments in renal impairment 136
LEVOFLOXACIN PLASMA CONCENTRATION IN CRITICALLY ILL PATIENTS 135
The effect of pathophysiology on pharmacokinetics in the critically ill patient - Concepts appraised by the example of antimicrobial agents 134
Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections 133
Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report 132
Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients 132
Procalcitonin-guided antibiotic therapy: An expert consensus 132
An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units 132
Totale 17.436
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.567
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.567
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.911 0 0 145 170 88 118 153 104 33 372 402 326
2022/20232.555 274 152 38 332 313 741 0 174 369 27 67 68
2023/2024668 126 53 20 10 114 79 20 57 71 40 28 50
2024/20253.674 111 318 216 126 137 198 189 253 433 281 470 942
2025/20267.701 573 860 823 575 1.105 702 1.015 266 564 626 343 249
2026/20271.132 212 556 364 0 0 0 0 0 0 0 0 0
Totale 31.593